Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial

Cancer Research and Treatment · Published 2026-07-28 · DOI 10.4143/crt.2026.0400

Free full text

Authors (25)

Wei Ren, Xiuping Lai, Guiying Bai, Yanqiong Liu, Hongtao Li, Huan Zhou, Shouman Wang, Qun Qin, Wei Li, Cuizhi Geng, Mingxia Wang, Xinshuai Wang, Yu Cao, Zhuang Yu, Caiwen Du, Wei Zhao, Shikai Wu, Yimin Cui, Pan Liu, Kaijing Zhao, Jiaman Lin, Xiaoyu Zhu, Yandan Yao, Yehui Shi, Herui Yao

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Ren, W., Lai, X., Bai, G., et al. (2026). Pyrotinib Plus Trastuzumab and Docetaxel with Different Antidiarrheal Strategies in Patients with HER2-Positive Recurrent or Metastatic Breast Cancer (PHAENNA): A Multicenter, Phase 1 Trial. Cancer Research and Treatment. https://doi.org/10.4143/crt.2026.0400

Related articles